Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Agios Pharmaceuticals, Inc.

Biotech Cost Dynamics: Lantheus vs. Agios

__timestampAgios Pharmaceuticals, Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 2014100371000176081000
Thursday, January 1, 2015141827000157939000
Friday, January 1, 2016220163000164073000
Sunday, January 1, 2017292681000169243000
Monday, January 1, 20181397000168489000
Tuesday, January 1, 20191317000172526000
Wednesday, January 1, 20202805000200649000
Friday, January 1, 202118777000237513000
Saturday, January 1, 20221704000353358000
Sunday, January 1, 20239504000586886000
Monday, January 1, 20244165000
Loading chart...

Infusing magic into the data realm

Cost of Revenue: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating comparison of the cost of revenue for Lantheus Holdings, Inc. and Agios Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Lantheus Holdings consistently outpaced Agios Pharmaceuticals in cost of revenue, peaking in 2023 with a staggering 587% increase from its 2014 figures. In contrast, Agios Pharmaceuticals experienced a more volatile trajectory, with a significant drop in 2018 and 2019, where costs plummeted by over 99% compared to 2017. This fluctuation highlights the challenges and unpredictability in the biotech sector. As Lantheus Holdings continues to expand its operations, its cost of revenue reflects a steady growth, while Agios Pharmaceuticals' figures suggest a strategic shift or restructuring during the mid-2010s.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025